Recent Comments

Comment RSS

Psoriasis Prognosis

Psoriasis is a lifelong condition. There is currently no cure but various treatments can help to control the symptoms.

Many of the most effective agents used to treat severe psoriasis carry an increased risk of significant morbidity including skin cancers, lymphoma and liver disease. However, the majority of people's experience of psoriasis is that of minor localized patches, particularly on the elbows and knees, which can be treated with topical medication.

Psoriasis can get worse over time but it is not possible to predict who will go on to develop extensive psoriasis or those in whom the disease may appear to vanish. Individuals will often experience flares and remissions throughout their lives. Controlling the signs and symptoms typically requires lifelong therapy.

According to one study, psoriasis is linked to 2.5-fold increased risk for non melanoma skin cancer in men and women, with no preponderance of any specific histologic subtype of cancer. This increased risk could also be attributed to antipsoriatic treatment.

Further Reading


This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article on "Psoriasis" All material adapted used from Wikipedia is available under the terms of the GNU Free Documentation License. Wikipedia® itself is a registered trademark of the Wikimedia Foundation, Inc.

Recent Psoriasis News

DARA BioSciences receives NASDAQ non-compliance noticeOn March 16, 2010, DARA BioSciences, Inc. received notice from the Listing Qualifications Staff of The NASDAQ Stock Market LLC indicating that the Company had not timely regained compliance with the $...ASCO Scientific Program 2010: Provectus Pharmaceuticals' Phase 2 data on PV-10 accepted for presentationProvectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced today that data from its Phase 2 study of PV-10 for metastatic melanoma has been acce...NexACT technology demonstrates ability to deliver Taxol subcutaneouslyNexMed, Inc., a specialty CRO and a developer of products based on the NexACT® technology, today announced that pre-clinical results from the research and development group at its Bio-Quant subsidiary...Metastatic melanoma: Involvement of immune system in response to PV-10 therapyProvectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced today that Dr. Sanjiv Agarwala, in his presentation at the Seventh International Symp...Manhattan Pharmaceuticals to merge with Ariston PharmaceuticalsManhattan Pharmaceuticals, Inc. today announced it has entered into a definitive agreement and plan of merger and completed the merger transaction with Ariston Pharmaceuticals, Inc., a privately-held,...
News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide.